1. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.
- Author
-
Rossi, S., Mataluni, G., Codec, C., Fiore, S., Buttari, F., Musella, A., Castelli, M., Bernardi, G., and Centonze, D.
- Subjects
- *
ANTICONVULSANTS , *MULTIPLE sclerosis , *CHRONIC pain , *PHARMACEUTICAL research , *CLINICAL trials - Abstract
Background and purpose: Central neuropathic pain (CNP) is a prevalent and distressing symptom in patients with multiple sclerosis (MS). The anticonvulsant levetiracetam (LEV) has been shown to be efficacious in some types of CNP, but its efficacy in MS-related CNP has not been confirmed. Methods: To investigate the tolerability and potential effects of LEV against CNP in MS subjects, we performed a single-center, prospective, randomized, single-blind, placebo-controlled study in twenty patients with MS and CNP. Outcomes before and during the 3-month study were assessed using validated measures of pain, depression, disability and quality of life. Results: The medication was well tolerated and analysis revealed a significant difference between the LEV and placebo arm in all study outcomes related to pain (mean pain intensity score, mean pain difference, percentage of patients with a clinically significant pain reduction). Furthermore, the individual quality of life rating improved in treated patients, showing a significant correlation with pain reduction. Conclusions: These findings suggest that further studies with larger samples of patients be carried out in order to confirm the efficacy of LEV in MS-related CNP population. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF